The estimated Net Worth of Patrick J. Christmas is at least $2.19 Million dollars as of 12 February 2021. Mr Christmas owns over 4,701 units of Regenxbio Inc stock worth over $267,838 and over the last 8 years he sold RGNX stock worth over $1,311,312. In addition, he makes $613,141 as Chief Legal Officer at Regenxbio Inc.
Sign up
Mr D RGNX stock SEC Form 4 insiders trading
Mr has made over 16 trades of the Regenxbio Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 4,701 units of RGNX stock worth $56,882 on 12 February 2021.
The largest trade he's ever made was exercising 30,000 units of Regenxbio Inc stock on 9 May 2018 worth over $363,000. On average, Mr trades about 5,352 units every 39 days since 2016. As of 12 February 2021 he still owns at least 21,073 units of Regenxbio Inc stock.
You can see the complete history of Mr Christmas stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Patrick J. Christmas II, J.D. biography
Patrick J. Christmas II, J.D. is the Chief Legal Officer at Regenxbio Inc.
What is the salary of Mr D?
As the Chief Legal Officer of Regenxbio Inc, the total compensation of Mr D at Regenxbio Inc is $613,141. There are 9 executives at Regenxbio Inc getting paid more, with Kenneth Mills having the highest compensation of $6,147,270.
How old is Mr D?
Mr D is 50, he's been the Chief Legal Officer of Regenxbio Inc since . There are 16 older and 3 younger executives at Regenxbio Inc. The oldest executive at Regenxbio Inc is Allan Fox, 72, who is the Chairman of the Board.
What's Mr D's mailing address?
Patrick's mailing address filed with the SEC is C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.
Insiders trading at Regenxbio Inc
Over the last 9 years, insiders at Regenxbio Inc have traded over $44,148,392 worth of Regenxbio Inc stock and bought 175,000 units worth $3,850,000 . The most active insiders traders include Llc Fmr, Argeris N Karabelas, and Edgar Engleman. On average, Regenxbio Inc executives and independent directors trade stock every 15 days with the average trade being worth of $238,185. The most recent stock trade was executed by Argeris N Karabelas on 3 September 2024, trading 10,000 units of RGNX stock currently worth $37,600.
What does Regenxbio Inc do?
regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.
What does Regenxbio Inc's logo look like?
Complete history of Mr Christmas stock trades at Regenxbio Inc
Regenxbio Inc executives and stock owners
Regenxbio Inc executives and other stock owners filed with the SEC include:
-
Kenneth Mills,
President, Chief Executive Officer, Executive Director -
Steve Pakola,
Senior Vice President, Chief Medical Officer -
Vittal Vasista,
Chief Financial Officer, Senior Vice President -
Olivier Danos,
Senior Vice President, Chief Scientific Officer -
Curran Simpson,
Senior Vice President - Product Development, Chief Technology Officer -
Kenneth T. Mills,
Pres, CEO & Director -
Vittal K. Vasista,
Chief Financial Officer -
Dr. Olivier Danos Ph.D.,
Chief Scientific Officer -
Curran M. Simpson M.S.,
Chief Operations & Technology Officer -
Patrick J. Christmas II, J.D.,
Chief Legal Officer -
Patrick J. Christmas II,
Chief Legal Officer -
Dr. Stephen Pakola,
Chief Medical Officer -
Luke Beshar,
Independent Director -
David Stump,
Independent Director -
Daniel Abdun-Nabi,
Independent Director -
A. N. Karabelas,
Lead Independent Director -
Daniel Tasse,
Independent Director -
Alexandra Glucksmann,
Independent Director -
Allan Fox,
Chairman of the Board -
Dr. Laura A. Coruzzi J.D., Ph.D.,
Sr. VP of Intellectual Property -
Ram Palanki,
Sr. VP of Commercial Strategy & Operations -
Dr. Laura A. Coruzzi,
Sr. VP of Intellectual Property -
Shiva G. Fritsch,
Chief People Officer -
Andrew Yost,
VP of Corp. Devel. -
Tricia Truehart,
VP of Investor Relations & Corp. Communications -
Stephen Yoo,
Chief Medical Officer -
Llc Fmr,
10% owner -
Camille D Samuels,
Director -
Faraz Ali,
Chief Business Officer -
Edgar Engleman,
Director -
James E Deerfield Mgmt L.P....,
-
Donald J Jr Hayden,
-
Patrick J. Christmas,
Chief Legal Officer -
Jean Bennett,
-
George V Migausky,
-
Jennifer Zachary,